<DOC>
	<DOCNO>NCT02171260</DOCNO>
	<brief_summary>This Phase 1 study eribulin mesylate pediatric patient recurrent refractory solid tumor ( exclude CNS ) , include lymphoma . Eribulin mesylate administer intravenously , per day Days 1 8 21-day cycle . This study aim determine MTD and/or RP2D regimen Part A1 ( patient great equal 12 month le 18 year ) . Part A2 enroll infant ( great 6 month le 12 month ) one dose level behind dose level patient Part A1 enrolling , order maximize safety infant subject . Additionally , study aim describe toxicity pharmacokinetics eribulin mesylate administer child . In preliminary manner , antitumor effect eribulin mesylate also describe .</brief_summary>
	<brief_title>This Phase 1 Study Eribulin Mesylate Pediatric Patients With Recurrent Refractory Solid Tumors ( Excluding CNS ) , Including Lymphomas .</brief_title>
	<detailed_description />
	<criteria>Inclusion Criteria Patients must great equal 12 month le 18 year age time study enrollment . Patients must great 6 month le 12 month age time study enrollment . Patients enroll one dose level behind dose level patient Part A1 enrol . Patients refractory recurrent solid tumor lymphomas , exclude CNS tumor , eligible . Patients must histologic verification malignancy original diagnosis relapse . Patients primary CNS tumor , know CNS metastasis , prior history CNS metastases eligible . Patients must either measurable evaluable disease . Patient 's current disease state must one know curative therapy therapy proven prolong survival acceptable quality life . Karnofsky great equal 50 % patient great 16 year age Lansky great equal 50 patient less equal 16 year age . Patients unable walk paralysis , wheelchair , consider ambulatory purpose assess performance score . Patients must fully recover acute toxic effect prior anticancer chemotherapy . 1 . Myelosuppressive chemotherapy : At least 21 day last dose myelosuppressive chemotherapy ( 42 day prior nitrosourea ) . 2 . Hematopoietic growth factor : At least 14 day last dose longacting growth factor ( e.g . Neulasta ) 7 day shortacting growth factor . For agent know adverse event occur beyond 7 day administration , period must extend beyond time adverse event know occur . The duration interval must discuss study chair . 3 . Biologic ( antineoplastic agent ) : At least 14 day last dose biologic agent . For agent know adverse event occur beyond 14 day administration , period must extend beyond time adverse event know occur . The duration interval must discuss study chair . 4 . Immunotherapy : At least 42 day completion type immunotherapy , e.g . tumor vaccine . 5 . Monoclonal antibody : At least 3 halflives antibody last dose monoclonal antibody . 6 . XRT : At least 14 day local palliative XRT ( small port ) ; At least 150 day must elapse prior TBI , craniospinal and/or entire spinal XRT great equal 50 % radiation pelvis ; At least 42 day must elapse substantial BM radiation . 7 . Stem Cell Infusion without TBI : No evidence active graft vs. host disease least 84 day must elapse transplant stem cell infusion . Adequate Bone Marrow Function Defined : Peripheral absolute neutrophil count ( ANC ) great equal 1000/mm^3 Platelet count great equal 100,000/mm^3 ( transfusion independent , define receive platelet transfusion least 7 day prior enrollment ) . Hemoglobin ( Hb ) least 8 g/dL baseline ( blood transfusion allow screening period correct Hb value less 8g/dL ) . All patient enrol study must evaluable hematologic toxicity . Creatinine clearance radioisotope GFR great equal 70ml/min/1.73 m^2 A serum creatinine base age/gender follow : Maximum Serum Age Creatinine ( mg/dL ) Male Female 6 month less 1 year 0.5 0.5 1. less 2 year 0.6 0.6 2. less 6 year 0.8 0.8 6 less 10 year 1 1 10 less 13 year 1.2 1.2 13 less 16 year 1.5 1.4 great 16 year 1.7 1.4 The threshold creatinine value Table derive Schwartz formula estimate GFR ( Schwartz et al . J. Peds , 106:522 , 1985 ) utilize child length stature data publish CDC . Bilirubin ( sum conjugate unconjugated ) less equal 1.5 x upper limit normal ( ULN ) age SGPT ( ALT ) less equal 110 U/L . For purpose study , ULN SGPT 45 U/L . SGOT ( AST ) less equal 125 U/L . For purpose study , ULN SGOT 50 U/L . Serum albumin great equal 2 g/dL . Shortening fraction great equal 27 % echocardiogram , ejection fraction great equal 50 % gate radionuclide study . QTc le equal 480 msec . Note : Patients Grade 1 prolonged QTc ( 450480 msec ) time study enrollment correctable cause prolong QTc address possible ( i.e . electrolyte , medication ) . See Appendix II list drug prolong QTc . All patient and/or parent legally authorize representative must sign write informed consent . Assent , appropriate , obtain accord institutional guideline . Patients must willing comply aspect protocol . Patients know human immunodeficiency virus ( HIV ) CD4 T cell count great equal 500 cells/mm3 require antiretroviral therapy eligible . Exclusion Criteria Pregnant breastfeed woman enter study due risk fetal teratogenic adverse event see animal study . Pregnancy test must obtain girl postmenarchal . Males female reproductive potential may participate unless agree use effective double barrier contraceptive method entire period receive protocol therapy . Patients receive corticosteroid stable decrease dose corticosteroid least 7 day prior enrollment eligible . Patients currently receive another investigational drug eligible . Patients currently receive anticancer agent eligible . Patients receive cyclosporine , tacrolimus agent prevent graftversushost disease post bone marrow transplant eligible trial . Patients receive drug prolong QTc eligible . Patients receive prior therapy eribulin mesylate eligible . Patients hypersensitivity excipients study drug eligible . The excipients ethanol , hydrochloric acid , sodium hydroxide water injection . Patients prior history viral hepatitis ( B C ) demonstrate positive serology ( presence antigen ) uncontrolled infection require treatment eligible . Patients great Grade 1 peripheral sensory neuropathy great Grade 1 peripheral motor neuropathy grade accord Modified ( `` Balis '' ) Pediatric Scale Peripheral Neuropathies eligible . Patients know congestive heart failure , symptomatic LV ejection fraction 50 % shorten fraction le 27 % eligible . Patients congenital long QT syndrome , bradyarrhythmias , QTc great 480 msec eligible . Patients primary CNS tumor eligible . Patients prior history know metastatic CNS disease involvement eligible . ( Note : CNS image patient without known history CNS disease require clinically indicate ) . Patients plan follow invasive procedure eligible : Major surgical procedure , laparoscopic procedure , open biopsy significant traumatic injury within 28 day prior enrollment . Central line placement subcutaneous port placement consider major surgery must place least 3 day prior enrollment external line ( e.g . Hickman Broviac ) least 7 day prior enrollment subcutaneous port . Core biopsy within 7 day prior enrollment . Fine needle aspirate within 7 day prior enrollment . Patients know bone marrow involvement eligible . Patients receive prior solid organ transplantation eligible . Patients opinion investigator may able comply safety monitoring requirement study eligible .</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Tumors</keyword>
	<keyword>Lymphomas</keyword>
	<keyword>Solid Tumors</keyword>
	<keyword>Pediatric</keyword>
</DOC>